Genentech takes the health and safety of its patients, customers, employees, and local communities very seriously, and are actively responding to the global COVID-19 pandemic. Genentech knows that needs will continue to emerge over the coming weeks and months, and they are closely monitoring and evaluating the situation as it evolves.
For more information on Genentech's response to COVID-19, please visit its website.

Small Cell SMASHERS was founded in 2023 as a patient-centered advocacy and education community designed to challenge long-standing narratives about small cell lung cancer and restore a sense of voice, connection, and hope for patients and their loved ones.

ACCCBuzz spoke with Fox Chase Cancer Center to learn more about its partnership with Omniscope, a leader in advanced molecular profiling technology, in hopes of developing an assay that accurately predicts which patients will respond well to immunotherapy based on the presence of certain T-cell clones.

On Friday, April 17, ACCC welcomed oncology leaders from around the country to Washington, DC for the inaugural ACCC Leadership Summit, a forum designed for executive-level decision-makers to engage in strategic dialogue, peer-to-peer exchange, and actionable insights at the highest level of oncology leadership.

During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.
